Posts

Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression

Authors: Jianfeng Wang, Yunze Xu, Yun Zou, Liangsong Zhu, Baijun Dong, Jiwei Huang, Yonghui Chen, Wei Xue, Yiran Huang, Wen Kong & Jin Zhang Published in Tumor Biology October 2016 Abstract Renal cell carcinoma (RCC) is a common urologic tumor with a poor prognosis. Cannabinoid receptor 1 (CB1), which is a G protein-coupled receptor, has recently…

Cannabidiol: Assessing preclinical safety in ovarian and endometrial carcinoma cell lines

Authors: Shannon Rush, Arvinder K Kapur, Manish S. Patankar, Lisa Marie Barroilhet Published in Journal of Clinical Oncology May 2020   Abstract Background: Cancer patients use cannabidiol (CBD) for chemotherapy and cancer symptoms, though research of CBD safety and efficacy for these conditions are ongoing and mixed. We sought to determine endometrial (ECC1) and epithelial…

Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells.

Authors: Dacai Xu, Jianglin Wang, Zhenkang Zhou, Zhiwei He, Qing Zhao
Molecular Medicine Reports, December 2015

Hepatocellular carcinoma (HCC) is the leading cause of cancer-associated mortality worldwide; however, only limited therapeutic treatments are currently available. The present study aimed to investigate the effects of cannabinoids as novel therapeutic targets in HCC. In additi…

Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.

Authors: Katherine Ann Scott, Sini Shah, Angus George Dalgleish, Wai Man Liu
Anticancer Research, October 2013

Cannabinoids are the bioactive components of the Cannabis plant that display a diverse range of therapeutic qualities. We explored the activity of six cannabinoids, used both alone and in combination in leukaemic cells. Cannabinoids were cytostatic and caused a simultaneous ar…

The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas.

Authors: E Pérez-Gómez, C Andradas, J M Flores, M Quintanilla, J M Paramio, M Guzmán, C Sánchez
Oncogene, 16 May 2013

G protein-coupled receptors (GPCRs) control crucial physiological processes and their dysfunction contributes to various human diseases, including cancer. The orphan GPCR GPR55 was identified and cloned more than a decade ago, but very little is known about its physio-patholog…

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.

Authors: Sean D. McAllister, Ryuichi Murase, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, et al
Breast Cancer Research and Treatment, August 2011

Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Therefore, effective, targeted, and non-toxi…

Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1.

Authors: Balázs I. Tóth, Nóra Dobrosi, Angéla Dajnoki, Gabriella Czifra, Attila Oláh, et al
Journal of Investigative Dermatology, May 2011

We have recently shown that lipid mediators of the emerging endocannabinoid system (ECS) are key players of growth control of the human pilosebaceous unit. In this study, we asked whether the prototypic endocannabinoid anandamide (N-arachidonoylethanolamine, AEA) has a role in…

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Authors: Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, et al
Molecular Cancer Therapeutics, January 2010

The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma. It has bee…

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors: N. Olea-Herrero, D. Vara, S. Malagarie-Cazenave, I. Díaz-Laviada
British Journal of Cancer, 15 September 2009

BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti…

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.

Authors: Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia, Pierre-Yves Desprez
Molecular Cancer Therapeutics, November 2007

Invasion and metastasis of aggressive breast cancer cells is the final and fatal step during cancer progression, and is the least understood genetically. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Clear…

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.

Authors: Daniela Sarnataro, Simona Pisanti, Antonietta Santoro, Patrizia Gazzerro, et al
Molecular Pharmacology, October 2006

The endocannabinoid system has been shown to modulate key cell-signaling pathways involved in cancer cell growth. In this study, we show that cannabinoid receptor type 1 (CB1) antagonist Rimonabant (SR141716) inhibited human breast cancer cell proliferation, being more effecti…

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

Authors: Alessia Ligresti, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, et al
Journal of Pharmacology and Experimental Therapeutics, September 2006

Delta(9)-Tetrahydrocannabinol (THC) exhibits antitumor effects on various cancer cell types, but its use in chemotherapy is limited by its psychotropic activity. We investigated the antitumor activities of other plant cannabinoids, i.e., cannabidiol, cannabigerol, cannabichrom…